The pathogenic autoantibody-producing plasma cells in MG patients depend on IL-6-mediated survival signals, and these antibodies directly interfere with neuromuscular transmission, leading to characteristic muscle weakness. The gene discussed is IL6; the disease is myasthenia gravis.